The Institute of Cancer Research, London, strongly welcomes the news that 177Lu-PSMA-617, a potent radioactive medicine that searches for tumour cells to deliver a radioactive payload, has been approved by the US Food and Drug Administration (FDA) for treating some advanced prostate cancers.

The Institute of Cancer Research, London, has expressed disappointment that NICE has decided not to recommend olaparib for previously treated, hormone-relapsed metastatic prostate cancer.

Scientists at The Institute of Cancer Research, London, are working with the Cambridge-based immuno-oncology company Crescendo Biologics on its development of a potential ‘next generation’ immunotherapy.